209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
60 citations
,
September 2004 in “Pediatric Dermatology” In this study, a 10-year-old girl developed vitiligo and psoriasis during IFN-alfa treatment for chronic hepatitis B, with neither condition improving after stopping the therapy.
June 2016 in “Afro-Egyptian Journal of Infectious and Endemic Diseases” In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.
34 citations
,
August 2002 in “British Journal of Dermatology” This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.
8 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.